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Spironolactone – a Pilot Study 32 
 33 
Abstract 34 
Objectives:   Spironolactone improves outcome in dogs with advanced myxomatous mitral 35 
valve disease (MMVD).  Its efficacy in preclinical MMVD is unknown. Hypothesis; 36 
administration of spironolactone to dogs with compensated MMVD demonstrating risk 37 
factors for poorer prognosis will decrease the rate of disease progression.  Aim; to provide 38 
pilot data to evaluate preliminary effects and sample size calculation for a definitive clinical 39 
trial. 40 
Animals: Twenty-five client-owned dogs with MMVD with at least one of the following; left 41 
atrial-to-aortic ratio (LA:Ao) ≥1.5, normalized left ventricular internal diameter in diastole 42 
(LVIDdN) ≥1.6), N-terminal pro-B-type natriuretic peptide (NT-proBNP) >550pmol/L, 43 
cardiac troponin I (cTnI) >0.025ng/mL.  44 
Methods: Prospective, single-center, equally randomized, placebo-controlled, double-blinded, 45 
parallel grouped pilot study.  No dogs were receiving medications for cardiac disease prior to 46 
enrolment.  47 
Results: Twelve dogs received placebo; 13 received spironolactone.   One dog in the 48 
spironolactone group died suddenly, 1 developed congestive heart failure and 2 received 49 
suboptimal spironolactone doses.  At enrolment NT-proBNP was significantly higher in the 50 
spironolactone group (P=0.005).  LA:Ao (P=0.002) and LVIDdN (P=0.005) increased over 51 
time in the placebo group, but not the spironolactone group; the change did not differ 52 
significantly between groups.  The change in biomarker concentrations did not differ 53 
significantly between groups; there was a tendency towards an increase in NT-proBNP over 54 
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time in the placebo group.  Enrolment of 76 dogs would be necessary to demonstrate a 55 
difference in the change in LA:Ao over 6 months between groups.   56 
Conclusions: preliminary results support undertaking a larger clinical trial of treatment of 57 
dogs with preclinical MMVD with spironolactone. 58 
 59 
Keywords: preclinical disease, therapy, canine 60 
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Abbreviations: 62 
ACVIM American College of Veterinary Internal Medicine 
Ao Aorta 
CHF Congestive heart failure 
CKCS Cavalier King Charles spaniel 
cTnI Cardiac troponin I 
ECG Electrocardiogram 
ELISA Enzyme-linked immunosorbent assay 
LA Left atrium 
LA:Ao Ratio of left atrial to aortic root diameter 
LVIDd Left ventricular internal dimension in diastole 
LVIDd/ LVFWd 
Ratio of left ventricular end-diastolic dimension to left 
ventricular free wall thickness in diastole 
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LVIDdN 
Left ventricular end-diastolic dimension normalized for body 
weight 
LVIDs Left ventricular internal dimension in systole 
LVIDsN 
Left ventricular end-systolic dimension normalized for body 
weight 
LVFWd Left ventricular free wall thickness in diastole 
MMVD Myxomatous mitral valve disease 
NSAID Non-steroidal anti-inflammatory drug 
NT-proBNP N-terminal pro-B-type natriuretic peptide 
PCV Packed cell volume 
UAC Urinary aldosterone to creatinine ratio 
  63 
 6 
Introduction 64 
Myxomatous mitral valve disease (MMVD) is the commonest cause of cardiovascular 65 
disease in the dog [1, 2].   Valvular degeneration results in regurgitation of blood, leading to 66 
progressive volume overload of the left atrium and ventricle, which compensate by eccentric 67 
hypertrophy [3]. The American College of Veterinary Internal Medicine (ACVIM) 68 
classification system for MMVD describes four disease stages, from A (at risk) to D 69 
(decompensated congestive heart failure) [4].  The compensated, preclinical stage of the 70 
disease (stage B) is subdivided according to the absence (stage B1) or presence (stage B2) of 71 
evidence of compensatory hypertrophy, identified on the basis of chamber enlargement on 72 
radiography or echocardiography.  The rate of progression of the disease is variable and the 73 
development of heart failure is not an inevitable consequence of MMVD [5].
 
However, even 74 
with optimal medical therapy, once dogs with MMVD develop congestive heart failure 75 
(CHF), median survival is approximately 270 days [6].  Pimobendan has been shown to delay 76 
the onset of congestive heart failure in dogs with ACVIM class B2 MMVD [7].  Further 77 
therapeutic strategies, targeting different mechanisms of disease progression, might provide 78 
additional clinical benefit in dogs at risk of disease progression.  79 
   The identification of dogs at greatest risk of progression of MMVD is important in a 80 
disease with such variability of outcome. Evidence of cardiac remodelling, such as increased 81 
echocardiographic measurements of left atrial [5]
 
and left ventricular size, [8]
 
are associated 82 
with decreased survival times in dogs with MMVD.  Increases in secondary markers of 83 
myocardial stress and injury, specifically, serum N-terminal pro-B-type natriuretic peptide 84 
(NT-proBNP) > 524 pmol/L and/ or serum cardiac troponin I (cTnI) > 0.025 ng/mL, are also 85 
associated with poorer outcomes [9].  Increased left atrial size is associated with an increased 86 
risk of disease progression for dogs in ACVIM class B [10].
 
 87 
  Activation of the renin-angiotensin-aldosterone system is important in the pathophysiology 88 
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of cardiac remodelling in canine MMVD [11].  Via its actions on the mineralocorticoid 89 
receptor, aldosterone promotes fluid retention, leading to volume-overload and stimulates 90 
myocardial fibrosis [12].
  
Urinary aldosterone to creatinine ratio (UAC) is associated with the 91 
rate of change of left ventricular size in dogs with MMVD, suggesting that aldosterone 92 
production increases during periods of active remodelling [13].  Spironolactone is a 93 
mineralocorticoid receptor antagonist that has been shown to prolong survival times in dogs 94 
with advanced MMVD and CHF secondary to MMVD, when given in combination with 95 
standard therapy [14].  The use of spironolactone in dogs with compensated MMVD has not 96 
been reported, although a study investigating its effects in combination with benazepril is 97 
currently ongoing. 98 
  We hypothesized that chronic oral administration of spironolactone to dogs with 99 
compensated MMVD demonstrating risk factors known to be associated with decreased 100 
survival times (increased left atrial and ventricular size and increased serum NT-proBNP and 101 
cTnI), not receiving any other cardiovascular medications, would result in decreased rates of 102 
change of these risk factors over time.  The aim of the study was to provide pilot data to 103 
evaluate preliminary effects, drug safety and to calculate the number of dogs needed for a 104 
definitive clinical trial. 105 
 106 
Animals, Materials and Methods 107 
Study Design 108 
The design of this pilot study was single-centre, prospective, equally randomized, double-109 
blinded, parallel-grouped and placebo-controlled. Each dog participated in the study for a 110 
period of six months. The study was conducted in the United Kingdom.  The study was 111 
approved by the Royal Veterinary College Ethical Committee and specific informed owner 112 
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consent was obtained (unique reference number 2010 1039).   113 
 114 
Dogs 115 
Client-owned dogs of a variety of breeds with echocardiographically-confirmed MMVD were 116 
prospectively recruited between December 2010 and December 2013 from those already 117 
enrolled in a longitudinal study of canine MMVD in first opinion practice [8].  Dogs were 118 
referred to the longitudinal study by the veterinarians at 2 London-based first opinion 119 
practices after detection of a murmur consistent with mitral regurgitation at any stage in the 120 
natural history of the disease.  Echocardiography was performed to confirm the diagnosis of 121 
MMVD and to exclude the presence of other cardiac diseases. Diagnosis of MMVD was on 122 
the basis of characteristic abnormalities of the valve leaflets (thickening, prolapse, or both) 123 
and evidence of regurgitant flow across the valve detected by Doppler.  Dogs with any other 124 
cardiac disease or clinically relevant organ-related or systemic disease were not enrolled in 125 
the longitudinal study.  126 
  To be eligible for inclusion in the present study, a dog had to have echocardiographic 127 
evidence of MMVD, defined as above, and demonstrate at least one risk factor for disease 128 
progression (evidence of cardiomegaly (defined as left atrial to aortic ratio (LA:Ao) ≥ 1.5 129 
and/ or left ventricular end-diastolic dimension, normalized for body weight (LVIDdN)) > 130 
1.6 [8], serum NT-proBNP > 550pmol/L [9] and/ or serum cTnI > 0.025 ng/mL [9].  During 131 
the screening process, but not during the experimental phase, serum NT-proBNP was 132 
measured using the first-generation version of a commercially-available enzyme-linked 133 
immunosorbent assay (ELISA).c    134 
  Dogs were excluded from the study if they had any of the following: evidence of any 135 
congenital or acquired cardiac disease other than MMVD; evidence of kidney disease, 136 
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hypoadrenocorticism (on the basis of historical, physical examination and routine 137 
biochemical findings; ACTH stimulation tests were not performed), hyperkalemia, or 138 
hypernatremia; current or previous clinical signs of congestive heart failure or current 139 
medical therapy for cardiac disease.  The summary of product characteristics for Prilactone 140 
recommends that dogs treated concomitantly with spironolactone and non-steroidal anti- 141 
inflammatory drugs (NSAIDs) be correctly hydrated,d and so it was recommended that dogs 142 
should not receive NSAIDs, although this was not an absolute exclusion criterion.  143 
 144 
Randomization 145 
Randomization was by patient (dog). The study was initially designed to recruit 20 dogs.  146 
Prior to the enrolment phase, a numbered list of 20 random group assignments (either group 147 
A or group B) was compiled by drawing assignments from a hat. Dogs were assigned to 148 
groups according to the order in which they were enrolled in the study. Prospectively 149 
determined, prognostic factor balance was achieved by minimization to ensure that the 150 
number of cavalier King Charles spaniels (CKCS) was equal in each group [15]; briefly, if, in 151 
the latter stages of the recruitment phase (from dog number 11 onwards), enrolling a CKCS 152 
to the next group assignment according to the randomization list would have resulted in 153 
unbalancing of the groups, then the dog was assigned to the alternative treatment group. No 154 
other variable was considered prior to enrolment.  Data obtained from the first 20 dogs were 155 
analysed and reported in abstract forme and the decision made to recruit an additional 20 dogs 156 
to increase the statistical power of the study.  An additional numbered list of 20 random 157 
assignments (either group C or group D) was compiled in the same way to allow recruitment 158 
of additional dogs to the study in a blinded fashion after treatment allocation of groups A and 159 
B was revealed at the time of previous data analysis.  160 
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 161 
Blinding 162 
The investigators and owners were blinded to the treatment allocation.  Assignment of 163 
enrolled dogs to treatment groups was performed by a veterinary nurse to conceal allocation 164 
from the investigators responsible for measurement of the variables of interest.  Data for the 165 
first 20 dogs enrolled (groups A and B) was analyzed prior to recruitment of the additional 166 
dogs (groups C and D).e  The blinding codes for the treatment groups were held by the 167 
sponsor until the time of each data analysis.   168 
 169 
Trial medication 170 
Spironolactone verum (Prilactone 10 mg tablets)f was administered orally at a target dose of 2 171 
mg/kg SID, as per registered label instructions, and the dose adjusted to a suitable number of 172 
tablets.  Placebo was administered PO according to the calculated daily dose for 173 
spironolactone verum tablets and adjusted to a suitable number of placebo tablets.  The 174 
tablets and packaging of the verum and placebo were visually indistinguishable.  Dogs 175 
received tablets (verum or placebo) orally once daily for 6 months, unless otherwise stated. 176 
The dose of the study medication was not adjusted during the study period.  Additional 177 
appropriate medication was prescribed if clinical signs of cardiac failure developed during the 178 
study period. Participation was terminated if clinical signs of another significant medical 179 
condition occurred which required additional treatment or warranted euthanasia, or if adverse 180 
effects were observed which necessitated cessation of the therapy. A record was kept of other 181 
medication used. Compliance was monitored by counting the number of unused pills returned 182 
by the owner at the end of the study period. This number was compared with the expected 183 
number of pills remaining.  184 
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 185 
Schedule of Events  186 
Prior to enrolment, serum biochemistry and electrolyte measurements were performed.  187 
  At baseline, enrolled cases underwent a full evaluation, comprising recording of the history, 188 
measurement of systolic arterial blood pressure by Doppler sphygmomanometry,g physical 189 
examination, blood sampling, electrocardiography (ECG) and echocardiography, in that 190 
order. Electrocardiography was performed in right lateral recumbency and heart rate was 191 
measured from a 60-second recording of lead II. Treatment was initiated with either verum or 192 
placebo. Re-examinations were scheduled at day 14 and approximately 6 months after 193 
inclusion.  The tests performed at each study visit are summarized in Figure 1.   194 
 195 
Clinical Evaluation 196 
At inclusion, demographic characteristics (age, breed, sex and neutering status) were 197 
recorded.  Body weight and body condition score were recorded at each study visit.  198 
 199 
Blood sampling and Laboratory Analysis 200 
Blood was collected by jugular venepuncture into serum gel tubes and K3-EDTA-treated 201 
tubes. Free-catch urine samples were collected. Samples were chilled at 4°C for up to 6 hours 202 
before separation by centrifugation.  Packed cell volume (PCV) was measured prior to 203 
separation.  Serum and urine samples were transported to a commercial laboratory for 204 
measurement of routine biochemical parameters and electrolytes.h  The remaining serum and 205 
urine were stored at -80°C for batched analysis.  Urinary aldosterone concentrations were 206 
measured using a previously-validated, commercially-available radioimmunoassay [16] 207 
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following mild acid hydrolysis and extraction into ethyl acetate, as previously described [13].   208 
Serum aliquots were transported to the same commercial laboratory on dry ice.  Before 209 
analysis, the frozen serum was allowed to thaw slowly at room temperature. Concentrations 210 
of cTnI were measured using an ELISAi according to the manufacturer’s instructions. The 211 
use of this assay has been previously validated for canine samples [17].  Concentrations of 212 
NT-proBNP were measured using the second-generation version of a previously-validated 213 
canine NT-proBNP ELISAc according to the manufacturer’s instructions [18].  Serum 214 
biochemistry and electrolytes, NT-proBNP, cTnI, PCV and UAC were measured at the 215 
baseline visit.  On day 14, PCV, serum biochemistry and electrolytes and UAC were 216 
measured. Full clinical evaluation, plus measurement of PCV, serum biochemistry and 217 
electrolytes, NT-proBNP, cTnI and UAC, was repeated at the 6 month time point, unless 218 
otherwise stated.   219 
 220 
Echocardiography 221 
Echocardiography was performed at baseline and at the 6 month visit.  Echocardiographic 222 
examinations were performed by a single board-certified cardiologist (AB). Dogs were placed 223 
in right and then left lateral recumbency on an ultrasound examination table.  The 224 
echocardiographic examination was performed using an ultra-sound unitj equipped with 2–4 225 
MHz and 3–7 MHz phased array transducers and ECG monitoring. Standard imaging planes 226 
were digitally stored. Assessment of mitral valve structures was performed from the right 227 
parasternal long-axis view and the left apical 4-chamber view.  The LA:Ao was measured 228 
from the right parasternal short axis view, as previously described [19].  Left ventricular 229 
internal diameters in systole and diastole (LVIDs and LVIDd, respectively) and wall 230 
thicknesses were measured from M-mode obtained from the right parasternal short axis view.  231 
LVIDs was normalized for body weight (LVIDsN) by the formula: LVIDs/ (body weight 232 
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[kg])0.315[20].  LVIDd was normalized for body weight (LVIDdN) by the formula: LVIDd/ 233 
(body weight [kg])0.294[20].  The ratio of LVIDd to left ventricular free wall thickness in 234 
diastole (LVFWd) was calculated (LVIDd/ LVFWd) as an indirect estimate of wall stress.  235 
Measurements were recorded from at least 3 cardiac cycles and the mean value used in 236 
subsequent analyses. 237 
   The primary outcome comparisons of the study were comparisons of the change in LA:Ao, 238 
LVIDdN and serum NT-proBNP and cTnI between groups over a 6 month period. Secondary 239 
outcome comparisons were comparisons of the change in other variables (PCV, serum urea, 240 
creatinine and electrolyte concentrations, UAC, LVIDsN, LVIDd/ LVFWd ratio, E wave 241 
velocity, E/A wave ratio, heart rate and body weight) between groups over the same 6 month 242 
period and between-group comparisons at different time points (baseline and 2 and 26 weeks 243 
after enrolment).  Results are reported according to the Consolidated Standards of Reporting 244 
Trials 2010 guidelines for reporting parallel group randomized trials [21]. 245 
 246 
Statistical Analysis  247 
Data were analyzed on an intention to treat basis and data from all dogs that were randomly 248 
assigned were included. Statistical analyses were performed using commercially-available 249 
software.k Data were assessed for normality graphically and by use of the Shapiro-Wilk test. 250 
Results are reported as mean ± standard deviations for normally distributed continuous 251 
variables or median [range] for non-normally distributed variables. Repeated measures linear 252 
mixed models with the random effect of subject (dog) were constructed to compare the 253 
change in variables over time, and a compound symmetry (co)variance structure was 254 
assumed between residuals of the same subject (dog) in the model.  The effects of treatment 255 
group (spironolactone vs. placebo), time (treated as a continuous covariate) and interaction 256 
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between treatment group and time were included in the model. Residuals were assessed 257 
graphically for normality. Variables were logarithmically transformed if the residuals were 258 
not normally distributed. The assumption of homogeneity of variance was tested by plotting 259 
the predicted values against the residual values. Comparisons of continuous variables 260 
between groups at different time points were made using independent t-tests or Mann-261 
Whitney U tests, as appropriate. Fisher’s exact tests were used to compare proportions 262 
between groups at baseline.  A value of P ≤0.05 was considered significant. In view of the 263 
small sample size and the pilot nature of the study a value of P < 0.1 was considered to 264 
indicate a tendency towards significance.  A sample size calculation was performed on the 265 
basis of the data obtained from the present pilot study using commercially-available software, 266 
assuming α = 0.05 and β = 0.2 (i.e. power = 0.8).l 267 
 268 
Results 269 
Progress through the phases of the study is summarized in Figure 2. Twenty-five dogs with 270 
compensated MMVD diagnosed on the basis of echocardiographic findings were enrolled in 271 
the study. Due to the low rate of suitable dogs presenting to the larger longitudinal study, it 272 
proved impossible to recruit 40 dogs.  Twenty-four dogs had LVIDdN > 1.6 and/ or LA:Ao > 273 
1.5. Fifteen dogs had a previous measurement of serum cTnI > 0.025 pmol/L. Twenty-one 274 
dogs had a previous measurement of serum NT-proBNP > 550 pmol/L. All dogs met the 275 
inclusion criteria; 13 dogs demonstrated all three risk factors, 8 dogs demonstrated two of the 276 
risk factors and 4 dogs demonstrated one risk factor.  Baseline characteristics of the two 277 
groups are presented in Table 1.  There was no evidence for differences in age, body weight, 278 
gender or proportions of CKCS to other breeds between groups. Serum NT-proBNP 279 
concentrations were higher in the spironolactone treatment group compared with the placebo 280 
group (P = 0.005). At baseline there was a tendency for serum potassium (P = 0.078) to be 281 
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higher in the spironolactone treatment group compared with the placebo group. Group-wise 282 
comparisons were otherwise unremarkable. No evidence of kidney disease, 283 
hypoadrenocorticism, hyperkalemia, or hypernatremia was detected in any dog on serum 284 
biochemical and electrolyte analysis.  285 
   Twelve dogs (5 neutered females, 2 entire males and 5 neutered males) with ages ranging 286 
from 6.3 to 13.1 years and body weights ranging from 4.5 to 18.2 kg were assigned to receive 287 
placebo.  These dogs comprised 7 CKCS, 2 mixed breeds and 1 each of bichon frisé, lurcher 288 
and toy poodle.  No compliance problems, potential adverse drug reactions or adverse events 289 
were reported for dogs in this group. Two dogs had been receiving NSAIDs prior to, but not 290 
at the time of, recruitment. NSAID therapy was reinitiated by the primary veterinarian during 291 
the trial period in one of these dogs. NSAID therapy was initiated during the trial period in a 292 
third dog. 293 
   Thirteen dogs (2 neutered females and 11 neutered males) with ages ranging from 6.1 to 294 
13.4 years and body weights ranging from 1.8 to 23.3 kg were assigned to receive 295 
spironolactone. These dogs comprised 8 CKCS, 2 cross-breeds and 1 each of bichon frisé, 296 
collie and Chihuahua.  One dog in this group received a suboptimal dose of trial medication 297 
(1.3 mg/kg once daily) throughout the trial period, due to owner non- compliance. One dog 298 
was treated for seasonal allergic dermatitis during the trial period, during which time the trial 299 
medication was withdrawn for 10.6 weeks. Trial medication was reinstated following 300 
resolution of the dermatitis, which did not subsequently recur.  301 
   Two dogs in the spironolactone group suffered adverse events during the trial period (one 302 
dog developed congestive heart failure requiring medical management and one dog died 303 
suddenly). The dog that died suddenly was not known to be in congestive heart failure prior 304 
to death. There was no difference in the proportion of dogs experiencing adverse events 305 
between groups (P = 0.480).  One dog had been receiving NSAIDs prior to, but not at the 306 
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time of, recruitment. NSAID therapy was reinitiated by the primary veterinarian during the 307 
trial period; this was the dog that died suddenly, although the death was considered to be 308 
unrelated to NSAID therapy.  309 
   Results of repeated measures linear model analyses for the primary outcome comparisons 310 
are summarized in Table 2. Residuals were not normally distributed for serum cTnI. 311 
Following logarithmic transformation of this variable the residuals were normally distributed.  312 
Because baseline serum NT-proBNP measurements were higher in the group receiving 313 
spironolactone, baseline measurements were included in the model as a covariate for this 314 
variable. No significant differences were detected for the change over time of any variable 315 
between groups.  The change in serum NT-proBNP tended to be greater for the placebo group 316 
(P = 0.087).  There was a tendency for serum NT-proBNP concentrations to increase in the 317 
placebo group, but not in dogs receiving spironolactone (P = 0.073) (Figure 3).  Left atrial to 318 
aortic ratio (P = 0.002) and LVIDdN (P = 0.005) increased over time in the placebo group, 319 
but not in dogs receiving spironolactone ((P = 0.231 and P = 0.194, respectively, Figures 4 320 
and 5); however, in the absence of significant differences in the change over time between 321 
groups these findings should be interpreted with caution. 322 
  Results of repeated measures linear model analyses for the secondary outcome comparisons 323 
are summarized in Table 3. Residuals were not normally distributed for UAC, serum 324 
creatinine or E wave velocity. Following logarithmic transformation of these variables the 325 
residuals were normally distributed. There was a tendency for LVIDd/ LVFWd ratio to 326 
increase over time in the placebo group (P = 0.070), but not in dogs receiving spironolactone 327 
(P = 0.315). The change in LVIDd/ LVFWd ratio over time was not different between 328 
groups. There was a tendency for body weight to decrease in the dogs receiving 329 
spironolactone (P = 0.066), but not in the placebo group.  The change in body weight was not 330 
different between groups.  331 
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   Comparisons between groups at the 2 week time point are summarized in Table 4. No dogs 332 
were withdrawn from the study at this time point due to pharmacovigilance concerns. Urinary 333 
aldosterone to creatinine ratio was significantly higher in dogs receiving spironolactone than 334 
those receiving placebo (P = 0.006). There was a tendency for serum potassium to be higher 335 
in dogs receiving spironolactone than those receiving placebo (P = 0.098). There was no 336 
evidence of differences in any other variable between groups at this time point.  337 
   Comparisons between groups at the 6 month time point are summarized in Table 5. There 338 
was a tendency for serum NT-proBNP to be higher in dogs receiving spironolactone than 339 
those receiving placebo (P = 0.051). There was no evidence of differences in any other 340 
variable between groups at this time point.  341 
   A post-hoc sample size calculation was performed using the mean change in LA:Ao 342 
observed from these preliminary data, which suggested that a total sample of 76 dogs (38 per 343 
group) would be necessary to demonstrate a significant difference in the change in LA:Ao 344 
over 6 months between groups if one existed.  However, use of the 95% confidence intervals 345 
for the change in LA:Ao for the sample size calculation suggested that the range of total 346 
sample size required to demonstrate a difference is 36 to 2936 dogs. 347 
 348 
Discussion  349 
   The results of the present study suggest that a larger sample size (76 dogs) would be 350 
necessary to definitively test the hypothesis that spironolactone slows the rate of progression 351 
of preclinical MMVD.  Although none of the between groups comparisons reached statistical 352 
significance, this pilot study is likely to be underpowered to demonstrate such differences. 353 
Four dogs receiving spironolactone failed to adhere to the protocol throughout the entire six 354 
month study period; one died suddenly, one developed congestive heart failure necessitating 355 
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the addition of other therapy, one received a suboptimal dose of medication and 356 
administration of trial medication was suspended in one dog for part of the trial period. This 357 
is likely to have further reduced the power of the study to detect differences between the 358 
groups.  A post hoc sample size calculation was performed in order to inform the design of a 359 
subsequent, larger study that could be performed to determine whether a real treatment effect 360 
exists. Given the 95% confidence interval of the average change in LA:Ao, the number of 361 
dogs required could be as few as 36 or as many as 2936.  Because of the intrinsic unreliability 362 
of such a sample size prediction on the basis of data from a relatively small population it is 363 
possible that there is no treatment effect, in which case no difference between groups would 364 
be demonstrated even if an infinite number of dogs was studied.  No definitive conclusions 365 
regarding any effect of spironolactone on disease progression in dogs with MMVD can 366 
therefore be drawn on the basis of the results of this pilot study. 367 
   Echocardiographic measurements of cardiac size (LA:Ao and LVIDdN) increased over 368 
time in the placebo group but not in dogs receiving spironolactone, although no difference in 369 
the change over time was detected between groups.  This suggests that performing a larger, 370 
definitive clinical trial is warranted to further investigate whether treatment with 371 
spironolactone slows disease progression in dogs with preclinical MMVD.  Increasing LA:Ao
 
372 
and LVIDdN
 
are known to be associated with reduced survival times in dogs with MMVD 373 
[22]. It is possible that decreasing the rate of increase of cardiac size might delay the onset of 374 
congestive heart failure, although large, long-term studies are required to investigate this 375 
hypothesis.  376 
   The radiographic indices of cardiac size in CKCS with compensated MMVD increase in a 377 
non-linear fashion with disease progression, reaching their maximal rate of change in the 9 378 
months prior to the onset of congestive heart failure [23].
 
It was expected, therefore, that in 379 
this population of dogs with compensated MMVD and risk factors likely to be associated 380 
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with progression, echocardiographic indices of cardiac size would increase significantly over 381 
a six month period. The observation that LA:Ao and LVIDdN increased significantly in the 382 
placebo group suggests that this expectation was reasonable. Patients with MMVD that have 383 
higher NT-proBNP concentrations and greater heart size tend to have more advanced disease. 384 
Thus, since the group of dogs receiving spironolactone had significantly higher NT-proBNP 385 
concentrations at baseline it might have been expected that these dogs would have a more 386 
rapid rate of change than those in the placebo group. This might have contributed to the 387 
failure of the study to demonstrate a difference in the change over time in LA:Ao and 388 
LVIDdN.  Future studies could use stratification of randomization of recruited cases by 389 
echocardiographic indices of heart size and/ or serum NT-proBNP concentrations to ensure 390 
that treatment groups are balanced with respect to these variables. In a small pilot study this 391 
approach was not feasible. 392 
   Urinary aldosterone to creatinine ratio was higher in dogs receiving spironolactone 393 
compared with placebo at the 2 week time point but not at the 6 month time point. 394 
Mineralocorticoid receptor blockade by spironolactone increases aldosterone secretion by 395 
stimulation of renin production [24].
 
It was expected that UAC would remain higher in the 396 
group receiving spironolactone throughout the study period. However, data were missing for 397 
this variable on 21/ 69 (30.4%) occasions on which it should have been measured due to 398 
failure to obtain urine samples. This would have decreased the power of the study to detect 399 
significant differences in UAC between treatment groups. 400 
   There was a tendency for serum potassium concentrations to be higher in dogs treated with 401 
spironolactone at baseline and the 2 week time point.  Nevertheless, all measurements 402 
remained within the range of normal values and so this is not a source of pharmacovigilance 403 
concern nor has it been noted as a clinically significant adverse event in the published clinical 404 
trials involving spironolactone in dogs [25].  405 
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   There was no evidence that the serum cTnI concentrations changed over time in either 406 
treatment group.  Rapid increases in serum cTnI concentrations only occur late in the course 407 
of the disease, within the last 6 months of life of dogs that die due to MMVD [9].  A rapid 408 
increase in serum cTnI would not, therefore, be expected in dogs in the compensated phase of 409 
the disease.  410 
   Fractional shortening is usually increased in the compensated phase of MMVD, as the 411 
presence of mitral insufficiency results in altered loading conditions. LVIDsN does not, 412 
therefore, increase until the late stages of MMVD [22, 26].
  
In a similar fashion to serum 413 
cTnI, it would not therefore be expected that LVIDsN would rapidly increase over a six 414 
month period in this population of dogs.  415 
   Increased E wave velocities are indicative of increased ventricular filling pressures and the 416 
volume of the regurgitant jet [26].
  
The results of the present study suggest that ventricular 417 
filling pressures were not increasing and ventricular diastolic function was not declining in 418 
either treatment group, probably reflecting the relatively early stage of the disease in this 419 
population. E wave velocities >1.2 m/s have previously been shown to be associated with an 420 
increased risk of disease progression in dogs with ACVIM class B MMVD; [10]
 
the majority 421 
of dogs in the present study had E wave velocities <1.2 m/s at the baseline visit.  422 
  This study has a number of limitations.  Firstly, the sample size calculation suggests that on 423 
the basis of our own data 76 dogs would need to be studied in order to demonstrate a 424 
difference in the change in LA:Ao over 6 months between groups if one exists.  This pilot 425 
study was therefore underpowered to detect such a difference.  We have therefore referred to 426 
tendencies towards significance in the data with a more lenient P-value of < 0.1, while 427 
recognizing the risks of a type I statistical error inherent in this approach.  Secondly, no 428 
consensus exists with regard to determining optimal cut-offs for echocardiographic evidence 429 
of cardiomegaly in canine MMVD. In the present study, LA:Ao > 1.5 and / or LVIDdN > 430 
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1.6, were used to select dogs at risk of progression.  These represent relatively liberal criteria, 431 
as the upper 95% confidence interval for LVIDdN is 1.85 [20].  However, in the present 432 
study these cut-offs were used only as inclusion criteria, in an attempt to identify dogs with 433 
more advanced compensated MMVD that were more likely to experience disease progression 434 
over a 6 month period. Previous studies have demonstrated that dogs above cut-off values 435 
lower than the value of 1.85 are at increased risk of cardiac related mortality [8].  Thirdly, 436 
increases in serum cTnI are not specific for cardiac disease,[27, 28] and so use of this marker 437 
as an inclusion criterion has limitations.  Nevertheless, no dog was recruited solely on the 438 
basis of the cTnI measurement. 439 
   Fourthly, this study included a high proportion of CKCS. Urinary aldosterone to creatinine 440 
ratio has been shown to be higher in CKCS than non-CKCS breeds [13].  It is possible, 441 
therefore, that any benefit of mineralocorticoid receptor blockade might be greater in CKCS 442 
than other breeds. For this reason, the groups were balanced for numbers of CKCS by the 443 
minimization method; the trial was not, therefore, truly randomized. However, 444 
mineralocorticoid receptor antagonists have been shown to be beneficial in human patients, 445 
regardless of plasma aldosterone concentrations [29].
 
Large studies that allow for sub-446 
analyses according to breed are necessary to investigate whether breed- specific effects of 447 
spironolactone exist.  448 
   Finally, allocation concealment would ideally have been performed externally rather than 449 
by a member of the regular clinic team. Inadequate allocation concealment may lead to 450 
selection bias and hence produce spurious results. In the present study, however, every 451 
attempt was made to maintain allocation concealment and therefore avoid bias of this nature.  452 
 453 
Conclusions 454 
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The preliminary findings of this pilot study support undertaking a larger, definitive, 455 
prospective, randomized, placebo-controlled, double-blinded clinical trial to further evaluate 456 
the effect of spironolactone on disease progression in dogs with preclinical MMVD. 457 
 458 
Footnotes 459 
c Canine Cardiopet Nt-proBNP, IDEXX Laboratories, Westbrook, ME 460 
d http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-461 
_Product_Information/veterinary/000105/WC500063372.pdf 462 
e M.J. Hezzell, A. Boswood, J. Elliott. Treatment of dogs with compensated degenerative 463 
mitral valve disease (DMVD) with spironolactone. Journal of Veterinary Internal Medicine 464 
2012; 26:1517. 465 
f CEVA Santé Animale, Libourne, France 466 
g Park model 811 B, Perimed, Bury St. Edmonds, UK  467 
h IDEXX Laboratories, Wetherby, UK 468 
i Access Systems AccuTnI Assay, Beckman Coulter Inc., Fullerton, CA 469 
j Acuson Cypress, Siemens Medical Solutions, Siemens House, Oldbury, Bracknell, UK 470 
k IBM SPSS version 23, SPSS Inc., Chicago, IL 471 
l GLIMMPSE version 2.2.4, University of Colorado, Denver, CO  472 
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Figure 1: Summary flow diagram detailing the tests performed at each visit during the study 570 
period.  571 
 572 
 573 
 574 
 575 
 576 
 577 
 578 
 579 
 580 
 581 
 582 
 583 
 584 
 585 
ECG, electrocardiogram; PCV, packed cell volume; NT-proBNP, N-terminal B-type 586 
natriuretic peptide; cTnI, cardiac troponin I.  587 
  588 
Baseline: 
History, physical examination, ECG measurement and echocardiography 
Blood and urine sampling 
PCV, serum biochemistry and electrolytes and serum NT-proBNP and 
cTnI   
Urine aldosterone and creatinine 
Initiation of treatment (verum or placebo) 
Two weeks post-baseline: 
History and physical examination 
Blood and urine sampling 
PCV, serum biochemistry and electrolyte measurement  
Urine aldosterone and creatinine 
Six months post-baseline: 
History, physical examination, ECG measurement and echocardiography 
Blood and urine sampling 
PCV, serum biochemistry and electrolytes and serum NT-proBNP and 
cTnI   
Urine aldosterone and creatinine 
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Figure 2: Flow diagram of the progress through the phases of this parallel, randomized trial of 589 
two groups.  Analysis was on the basis of intention to treat.   590 
Allocated to receive placebo (n = 12) 
Received placebo (n = 12) 
Randomized (n = 25) 
Allocated to receive verum (n = 13) 
Received spironolactone (n = 13) 
 
Analyzed (n = 12) 
Excluded from analysis (n = 0)  
 
Analyzed (n = 13) 
Excluded from analysis (n = 0)  
 
Lost to follow up (n = 0) 
Discontinued medication 
Lost to follow up (n = 1): sudden death 
Did not receive medication per protocol 
(n = 2): 1 medication temporarily 
withdrawn, 1 given suboptimal dose 
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Figure 3: LA/Ao in dogs receiving placebo and those receiving spironolactone at baseline (n 591 
= 12 and 13, respectively) and at the 6 month time point (n = 12 and 12, respectively).  The 592 
central tendency represents the mean and the error bars represent the standard deviation. 593 
  594 
 31 
Figure 4: LVIDDN (cm/ [kg0.294]) in dogs receiving placebo and those receiving 595 
spironolactone at baseline (n = 12 and 13, respectively) and at the 6 month time point (n = 12 596 
and 12, respectively).  The central tendency represents the mean and the error bars represent 597 
the standard deviation. 598 
 599 
  600 
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Figure 5: Serum NT-proBNP concentrations (pmol/L) in dogs receiving placebo and those 601 
receiving spironolactone at baseline (n = 12 and 13, respectively) and at the 6 month time 602 
point (n = 12 and 11, respectively).  The central tendency represents the mean and the error 603 
bars represent the standard deviation. 604 
 605 
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Table 1: Comparisons of clinical, echocardiographic and biomarker data between dogs 607 
receiving placebo and those receiving spironolactone at baseline.   608 
Variable Group receiving 
placebo 
(n = 12) 
Group receiving 
spironolactone 
(n = 13) 
P value 
Age (years) 9.4 ±2.0 9.7 ±2.0 0.707 
CKCS (yes/ total) 7/ 12 9/ 13 0.688 
Sex (male/ total) 7/ 12 11/13 0.202 
Body weight (kg) 11.6 ±4.1 11.8 ±6.3 0.940 
Systolic blood pressure 
(mmHg) 
156.5 ±29.8 159.4 ±32.0 0.816 
Heart rate (ECG) (bpm) 117.3 ±25.0 117.2 ±25.7 0.992 
LA:Ao ratio 1.27 ±0.17 1.40 ±0.21 0.105 
LVIDdN (cm/[kg0.294]) 1.79 ±0.20 1.95 ±0.35 0.180 
LVIDsN (cm/[kg0.315]) 1.05 ±0.13 1.10 ±0.28 0.548 
LVIDd/ LVFWd ratio 4.06 ±0.63 4.46 ±0.96 0.229 
E wave velocity (m/s) 1.01 ±0.22 0.99 ±0.35 0.883 
E/ A wave ratio 1.37 ±0.22 1.40 ±0.50 0.857 
Serum NT-proBNP (pmol/L) 1006.0  
[541.0, 2108.0] 
2434.0  
[740.0, 3955.0] 
0.005 
Serum cTnI (ng/mL) 0.03  
[0.01, 0.16] 
0.03  
[0.01, 0.19] 
0.437 
UAC (g/mol) 0.079  
[0.044, 0.119] 
0.088  
[0.042, 0.165] 
0.744 
PCV (%) 42.7 ±6.4 40.9 ±4.6 0.439 
Serum urea (mmol/L) 5.3 ±2.2 6.0 ±1.9 0.426 
 34 
Serum creatinine (µmol/L) 68.9 [59.7, 146.3] 70.5 [52.5, 130.6] 0.810 
Serum Na+ (mmol/L) 147.7 ±2.5 147.8 ±2.0 0.893 
Serum K+ (mmol/L) 4.2 ±0.4 4.5 ±0.5 0.078 
Serum Cl- (mmol/L) 111.5 ±3.6 113.0 ±2.5 0.237 
 609 
All variables in the group receiving placebo included 12 dogs, except UAC (n = 10), E wave 610 
velocity (n = 11) and E/A ratio (n = 11).  All variables in the group receiving spironolactone 611 
included 13 dogs, except UAC (n = 9).  The P values for variables for which significant 612 
between-group differences were detected (P < 0.05) are highlighted in bold text. 613 
CKCS, cavalier King Charles spaniel; ECG, electrocardiogram; bpm, beats per minute; 614 
LA:Ao ratio, left atrial to aortic root ratio; LVIDdN, left ventricular end-diastolic diameter 615 
normalized for body weight; LVIDsN, left ventricular end-systolic diameter normalized for 616 
body weight; LVIDd/ LVFWd ratio, left ventricular end-diastolic diameter to left ventricular 617 
free wall thickness in diastole ratio; NT-proBNP, N-terminal B-type pro-natriuretic peptide; 618 
cTnI, cardiac troponin I; UAC, urinary aldosterone to creatinine ratio; PCV, packed cell 619 
volume; Na+, sodium ions; K+, potassium ions; Cl-, chloride ions.  620 
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Table 2: Repeated measures linear mixed model analysis of change over 6 months in 621 
variables of primary interest.  622 
Variable  P (between 
groups) 
Unit change in variable per 
month (B)  
[95% confidence interval] 
SE P (within 
group) 
Serum NT-proBNP (pmol/L) 
  Placebo group (n = 12) 
  Spironolactone group (n = 12) 
0.087  
54.93 [-5.58 to 115.45] 
 -18.50 [-78.23 to 41.24] 
 
29.22  
29.00 
 
0.073 
 0.529 
Log (Serum cTnI [ng/mL]) 
  Placebo group (n = 12) 
  Spironolactone group (n = 12) 
0.708  
-0.010 [-0.035 to 0.015]  
-0.004 [-0.028 to 0.021] 
 
0.012 
 0.012 
 
0.420 
 0.772 
LA:Ao ratio 
  Placebo group (n = 12) 
  Spironolactone group (n = 12) 
0.110  
0.020 [0.008 to 0.032]  
0.007 [-0.005 to 0.018] 
 
0.006 
 0.006 
 
0.002  
0.231 
LVIDdN (cm/[kg
0.294
]) 
  Placebo group (n = 12) 
  Spironolactone group (n = 12) 
0.223  
0.017 [0.006 to 0.029]  
0.007 [-0.004 to 0.019] 
 
0.006  
0.006 
 
0.005 
 0.194 
 623 
Repeated measures linear mixed model analysis of change over 6 months in variables of 624 
primary interest (LA:Ao ratio, LVIDdN and serum NT-proBNP and cTnI) for the verum and 625 
placebo groups. 626 
P (between groups): probability that the rate of change of the variable is different between the 627 
group receiving placebo and the group receiving spironolactone.   628 
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Table 3: Repeated measures linear mixed model analysis of change over 6 months in clinical, 629 
echocardiographic and biomarker parameters of secondary interest. 630 
Variable  P (between 
groups) 
Unit change in variable per 
month (B)  
[95% confidence interval] 
SE P (within 
group) 
PCV (%) 
  Placebo group (n = 9) 
  Spironolactone group (n = 10) 
0.792  
-0.06 [-0.41 to 0.29]  
0.01 [-0.35 to 0.36] 
 
0.17  
0.17 
 
0.729 
 0.977 
Serum urea (mmol/L) 
  Placebo group (n = 12) 
  Spironolactone group (n = 12) 
0.406  
0.01 [-0.15 to 0.17]  
0.11 [-0.06 to 0.27] 
 
0.08  
0.08 
 
0.903  
0.195 
Log (Serum creatinine [µmol/L]) 
  Placebo group (n = 12) 
  Spironolactone group (n = 12) 
0.223  
 
-0.001 [-0.006 to 0.004] 
 0.003 [-0.002 to 0.008] 
 
 
0.002  
0.002 
 
 
0.706 
 0.177 
Serum Na+ (mmol/L) 
  Placebo group (n = 12) 
  Spironolactone group (n = 12) 
0.407  
-0.071 [-0.254 to 0.113]  
0.036 [-0.144 to 0.216] 
 
0.091  
0.089 
 
0.441  
0.690 
Serum K+ (mmol/L) 
  Placebo group (n = 12) 
  Spironolactone group (n = 12) 
0.328  
0.028 [-0.011 to 0.067]  
0.001 [-0.037 to 0.039] 
 
0.019  
0.019 
 
0.157  
0.957 
Serum Cl- (mmol/L) 
  Placebo group (n = 12) 
0.713  
0.023 [-0.258 to 0.306] 
 
0.139 
 
0.871 
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  Spironolactone group (n = 12)  -0.050 [-0.327 to 0.228]  0.138  0.719 
Log (UAC[g/mol]) 
  Placebo group (n = 9) 
  Spironolactone group (n = 8) 
0.223  
0.017 [0.006 to 0.029]  
0.007 [-0.004 to 0.019] 
 
0.006  
0.006 
 
0.005  
0.194 
Body weight (kg) 
  Placebo group (n = 12) 
  Spironolactone group (n = 12) 
0.456  
-0.016 [-0.055 to 0.024]  
-0.036 [-0.074 to 0.002] 
 
0.019  
0.019 
 
0.428  
0.066 
LVIDsN (cm/[kg0.315]) 
  Placebo group (n = 12) 
  Spironolactone group (n = 12) 
0.839  
0.005 [-0.006 to 0.015]  
0.003 [-0.007 to 0.013] 
 
0.005  
0.005 
 
0.367  
0.527 
LVIDd/ LVFWd ratio 
  Placebo group (n = 12) 
  Spironolactone group (n = 12) 
0.531  
0.053 [-0.005 to 0.029]  
0.028 [-0.029 to 0.086] 
 
0.028  
0.028 
 
0.070  
0.315 
Log (E wave velocity [m/s]) 
  Placebo group (n = 11) 
  Spironolactone group ( n= 12) 
0.734  
0.001 [-0.006 to 0.009]  
-0.001 [-0.008 to 0.007] 
 
0.004  
0.003 
 
0.740  
0.887 
E/A ratio 
  Placebo group (n =11) 
  Spironolactone group (n = 12) 
0.876  
-0.004 [-0.034 to 0.026]  
-0.007 [-0.035 to 0.022] 
 
0.015  
0.014 
 
0.804  
0.625 
Heart rate (ECG) (bpm) 
  Placebo group (n = 12) 
  Spironolactone group (n = 12) 
0.477  
-0.066 [-1.684 to 1.553]  
-0.858 [-2.449 to 0.733] 
 
0.781  
0.768 
 
0.934  
0.276 
 631 
Repeated measures linear mixed model analysis of change over 6 months in clinical, 632 
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echocardiographic and biomarker parameters of secondary interest for the verum and placebo 633 
groups.  634 
P (between groups): probability that the rate of change of the variable is different between the 635 
group receiving placebo and the group receiving spironolactone.  636 
P (within group): probability that the rate of change over time within the group = 0.  637 
SE, standard error; for definitions of other abbreviations see legend to Table 1.  638 
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Table 4: Comparisons of selected clinical, echocardiographic and biomarker data between 639 
dogs receiving placebo and those receiving spironolactone at the 2 week time point.  640 
 641 
Comparisons of selected clinical, echocardiographic and biomarker data between dogs 642 
receiving placebo and those receiving spironolactone at the 2 week time point. All variables 643 
in the group receiving placebo included 10 dogs, except PCV and UAC, which each included 644 
7 dogs. All variables in the group receiving spironolactone included 10 dogs, except PCV, 645 
which included 9 dogs and UAC, which included 7 dogs. The P values for variables for 646 
which significant between-group differences were detected (P < 0.05) are highlighted in bold 647 
text.  648 
For definitions of abbreviations see legend to Table 1.  649 
Variable  Group receiving placebo 
(n = 10) 
Group receiving 
spironolactone 
(n = 10) 
P value 
UAC (g/mol)  0.063 [0.032, 0.077] 0.236 [0.125, 0.339] 0.006 
PCV (%)  46.0 ±7.8 42.9 ±7.4 0.428 
Serum urea (mmol/L)  6.3 ±2.2 6.4 ±2.0 0.925 
Serum creatinine (μmol/L)  
74.7 [63.4, 93.2] 
76.4 [67.7, 83.7] 0.940 
Serum Na+ (mmol/L)  
147.1 ±1.7 
147.3 ±1.1 0.780 
Serum K+
 
(mmol/L) 
4.5 ±0.2 
4.7 ±0.2 0.098 
Serum Cl- (mmol/L)  109.3 ±2.8 111.4 ±3.2 0.144 
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Table 5: Comparisons of clinical, echocardiographic and biomarker data between dogs 650 
receiving placebo and those receiving spironolactone at the 6 month time point.  651 
Variable  Group receiving placebo (n 
= 12) 
Group receiving 
spironolactone (n = 12) 
P value 
Body weight (kg)  11.5 ±4.2 11.5 ±6.9 0.986 
Heart rate (ECG) (bpm)  116.8 ±25.8 111.7 ±20.4 0.592 
LA:Ao ratio  1.39 ±0.25 1.46 ±0.18 0.427 
LVIDdN (cm/[kg0.294])  1.89 ±0.24 2.01 ±0.34 0.367 
LVIDsN (cm/[kg0.315])  1.08 ±0.18 1.11 ±0.28 0.747 
LVIDd/ LVFWd ratio  4.37 ±0.82 4.59 ±1.12 0.593 
E wave velocity (m/s)  1.02 ±0.19 0.96 ±0.28 0.539 
E/ A wave ratio  1.33 ±0.13 1.37 ±0.39 0.722 
NT-proBNP (pmol/L)  1188.5 [359.0, 3018.0] 1852.0 [765.0, 4128.0] 0.051 
cTnI (ng/mL)  0.025 [0.010, 0.150] 0.030 [0.010, 0.170] 0.378 
UAC (g/mol) 0.063 [0.010, 0.410] 0.125 [0.060, 0.370] 0.113 
PCV (%)  42.8 ±6.3 42.1 ±5.5 0.792 
Serum urea (mmol/ L)  5.7 ±1.7 6.7 ±3.5 0.364 
Serum creatinine (μmol/L)  76.1 [51.9, 146.3] 82.4 [54.1, 145.5] 0.514 
Serum Na+ (mmol/L)  147.1 ±1.0 147.9 ±1.4 0.127 
Serum K+ (mmol/L)  4.5 ±0.3 4.6 ±0.3 0.448 
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Serum Cl- (mmol/L)  111.0 ±2.6 112.5 ±3.6 0.258 
Comparisons of clinical, echocardiographic and biomarker data between dogs receiving 652 
placebo and those receiving spironolactone at the 6 month time point. All variables in the 653 
group receiving placebo included 12 dogs, except UAC (n = 9). All variables in the group 654 
receiving spironolactone included 12 dogs, except PCV (n = 11), NT-proBNP (n = 11) and 655 
UAC (n =6). 656 
For definitions of abbreviations see legend to Table 1.   657 
